Home > Insider Trading > Filing (0001582945-20-000006)

Filing Details

Accession Number:: 0001582945-20-000006
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-10 16:05:03
Reporting Period:: 2019-12-12

Accepted Time:: 2020-03-10 16:05:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1425627	Transbiotec Inc.	IMLE	Periodicals: Publishing Or Publishing & Printing (2721)	260731818

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1794353	John Gary Graham	6400 S. Fiddlers Green Circle Suite 525 Greenwood Village CO 80111		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-12-12	0	$0.00	0	No	4	P	Direct
Common Stock	Acquisiton	2020-02-15	0	$0.00	0	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Acquisiton	2019-12-12	1,000,000	$1,000,000.00	1,000,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,000,000	2019-12-12	2029-12-22	No	4	P	Indirect

Footnotes

On December 12, 2019, the Reporting Person received irrevocable proxies from five (5) shareholders of the Issuer for an aggregate of 112,908,180 shares of the Issuer's common stock equaling approximately 52.6% of the Issuer's outstanding voting rights. The proxies are for the limited purpose of approving all transactions related to the Asset Purchase Agreement entered into by and between the Issuer and IDTEC dated May 6, 2019, as amended. As a result of receiving these proxies the Reporting Person may be deemed to beneficially own, pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act"), in excess of 10% of the outstanding common stock of the Issuer. The Reporting Person disclaims beneficial ownership of these shares for the purposes of Section 16 of the Act and the filing of this Form 4 shall not be an admission that the Reporting Person is the beneficial owner of such shares.
On February 15, 2020, the Reporting Person received an additional irrevocable proxy from one of the same shareholders for an aggregate of 24,353,116 additional shares of the Issuer's common stock in accordance with the same terms and disclaimer set forth in footnote (1) above.
The Issuer's 8% Series A-1 Convertible Preferred Stock is convertible into shares of the Issuer's common stock at the rate of $1 per share (which is the per share purchase price the Reporting Person paid for the 8% Series A-1 Convertible Preferred Stock).
The shares of 8% Series A-1 Convertible Preferred Stock do not expire.